By Stephen Nakrosis

 

Amgen Inc. said Wednesday the U.S. Food and Drug Administration approved Kyprolis in a combination regime to treat certain adult patients with relapsed or refractory multiple myeloma.

The company said the FDA expanded Kyprolis' prescribing information to include its use with Darzalex Faspro, or daratumumab and hyaluronidase-fihj, and dexamethasone to treat adults with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

Amgen said the expansion was supported by an ongoing Phase 2 trial evaluating Darzalex Faspro in combination with four standard-of-care treatment regimens in patients with multiple myeloma.

At 1:50 p.m. ET, Amgen shares were trading 2.4% higher at $203.59.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

December 01, 2021 14:12 ET (19:12 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Amgen Charts.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Amgen Charts.